148 related articles for article (PubMed ID: 32124272)
21. Certolizumab treatment during late pregnancy in patients with rheumatic diseases: Low drug levels in cord blood but possible risk for maternal infections. A case series of 13 patients.
Förger F; Zbinden A; Villiger PM
Joint Bone Spine; 2016 May; 83(3):341-3. PubMed ID: 26617214
[TBL] [Abstract][Full Text] [Related]
22. A Phase III Study Evaluating Continuation, Tapering, and Withdrawal of Certolizumab Pegol After One Year of Therapy in Patients With Early Rheumatoid Arthritis.
Weinblatt ME; Bingham CO; Burmester GR; Bykerk VP; Furst DE; Mariette X; van der Heijde D; van Vollenhoven R; VanLunen B; Ecoffet C; Cioffi C; Emery P
Arthritis Rheumatol; 2017 Oct; 69(10):1937-1948. PubMed ID: 28666080
[TBL] [Abstract][Full Text] [Related]
23. Certolizumab pegol for treating axial spondyloarthritis.
Desmarais J; Beier S; Deodhar A
Expert Opin Biol Ther; 2016 Aug; 16(8):1059-64. PubMed ID: 27366922
[TBL] [Abstract][Full Text] [Related]
24. Impact of certolizumab pegol on patient-reported outcomes in rheumatoid arthritis and correlation with clinical measures of disease activity.
Pope J; Bingham CO; Fleischmann RM; Dougados M; Massarotti EM; Wollenhaupt J; Duncan B; Coteur G; Weinblatt ME
Arthritis Res Ther; 2015 Nov; 17():343. PubMed ID: 26614481
[TBL] [Abstract][Full Text] [Related]
25. Certolizumab pegol (CDP870) for rheumatoid arthritis in adults.
Ruiz Garcia V; Burls A; Cabello JB; Vela Casasempere P; Bort-Marti S; Bernal JA
Cochrane Database Syst Rev; 2017 Sep; 9(9):CD007649. PubMed ID: 28884785
[TBL] [Abstract][Full Text] [Related]
26. Safety and efficacy of certolizumab pegol in a real-life cohort of patients with psoriasis and psoriatic arthritis.
Carubbi F; Fidanza R; Palmieri M; Ventura A; Tambone S; Cipriani P; Giacomelli R; Fargnoli MC
J Dermatolog Treat; 2020 Nov; 31(7):692-697. PubMed ID: 30963798
[No Abstract] [Full Text] [Related]
27. Sustained efficacy, safety and patient-reported outcomes of certolizumab pegol in axial spondyloarthritis: 4-year outcomes from RAPID-axSpA.
van der Heijde D; Dougados M; Landewé R; Sieper J; Maksymowych WP; Rudwaleit M; Van den Bosch F; Braun J; Mease PJ; Kivitz AJ; Walsh J; Davies O; Bauer L; Hoepken B; Peterson L; Deodhar A
Rheumatology (Oxford); 2017 Sep; 56(9):1498-1509. PubMed ID: 28498975
[TBL] [Abstract][Full Text] [Related]
28. New Approaches in Tumor Necrosis Factor Antagonism for the Treatment of Psoriatic Arthritis: Certolizumab Pegol.
Cauli A; Piga M; Lubrano E; Marchesoni A; Floris A; Mathieu A
J Rheumatol Suppl; 2015 Nov; 93():70-2. PubMed ID: 26523062
[TBL] [Abstract][Full Text] [Related]
29. Improvements in productivity and increased participation in daily activities over 52 weeks of certolizumab pegol treatment of rheumatoid arthritis: results of a Belgian observational study.
Westhovens R; Ravelingien I; Vandevyvere K; Pansar I; Purcaru O; Kumke T; Gyselbrecht L
Acta Clin Belg; 2019 Oct; 74(5):342-350. PubMed ID: 30160189
[No Abstract] [Full Text] [Related]
30. Head-to-head comparison of certolizumab pegol versus adalimumab in rheumatoid arthritis: 2-year efficacy and safety results from the randomised EXXELERATE study.
Smolen JS; Burmester GR; Combe B; Curtis JR; Hall S; Haraoui B; van Vollenhoven R; Cioffi C; Ecoffet C; Gervitz L; Ionescu L; Peterson L; Fleischmann R
Lancet; 2016 Dec; 388(10061):2763-2774. PubMed ID: 27863807
[TBL] [Abstract][Full Text] [Related]
31. Certolizumab pegol for the treatment of psoriatic arthritis and plaque psoriasis.
Esposito M; Carubbi F; Giunta A; Alunno A; Giacomelli R; Fargnoli MC
Expert Rev Clin Immunol; 2020 Feb; 16(2):119-128. PubMed ID: 31917928
[No Abstract] [Full Text] [Related]
32. Early Disease Activity or Clinical Response as Predictors of Long-Term Outcomes With Certolizumab Pegol in Axial Spondyloarthritis or Psoriatic Arthritis.
van der Heijde D; Deodhar A; Fleischmann R; Mease PJ; Rudwaleit M; Nurminen T; Davies O
Arthritis Care Res (Hoboken); 2017 Jul; 69(7):1030-1039. PubMed ID: 27696727
[TBL] [Abstract][Full Text] [Related]
33. Factors associated with successful discontinuation of certolizumab pegol in early rheumatoid arthritis.
Tanaka Y; Atsumi T; Yamamoto K; Takeuchi T; Yamanaka H; Ishiguro N; Eguchi K; Watanabe A; Origasa H; Shoji T; Miyasaka N; Koike T
Int J Rheum Dis; 2020 Mar; 23(3):316-324. PubMed ID: 31957303
[TBL] [Abstract][Full Text] [Related]
34. Modeled Health Economic Impact of a Hypothetical Certolizumab Pegol Risk-Sharing Scheme for Patients with Moderate-to-Severe Rheumatoid Arthritis in Finland.
Soini E; Asseburg C; Taiha M; Puolakka K; Purcaru O; Luosujärvi R
Adv Ther; 2017 Oct; 34(10):2316-2332. PubMed ID: 28975568
[TBL] [Abstract][Full Text] [Related]
35. Efficacy and safety of bimekizumab as add-on therapy for rheumatoid arthritis in patients with inadequate response to certolizumab pegol: a proof-of-concept study.
Glatt S; Taylor PC; McInnes IB; Schett G; Landewé R; Baeten D; Ionescu L; Strimenopoulou F; Watling MIL; Shaw S
Ann Rheum Dis; 2019 Aug; 78(8):1033-1040. PubMed ID: 31177099
[TBL] [Abstract][Full Text] [Related]
36. Clinical, Patient-Reported, and Ultrasound Outcomes from an Open-Label, 12-week Observational Study of Certolizumab Pegol in Spanish Patients with Rheumatoid Arthritis with or without Prior Anti-TNF Exposure.
Blanco FJ; Rubio-Romero E; Sanmartí R; Díaz-Torné C; Talavera P; Dunkel J; Naredo E;
Reumatol Clin (Engl Ed); 2020; 16(5 Pt 1):345-352. PubMed ID: 30236749
[TBL] [Abstract][Full Text] [Related]
37. Clinical, Ultrasound, and Predictability Outcomes Following Certolizumab Pegol Treatment (with Methotrexate) in Patients with Moderate-to-Severe Rheumatoid Arthritis: 52-Week Results from the CZP-SPEED Study.
Sarzi-Puttini P; Filippucci E; Adami S; Meroni PL; Batticciotto A; Idolazzi L; De Lucia O; Talavera P; Kumke T; Grassi W
Adv Ther; 2018 Aug; 35(8):1153-1168. PubMed ID: 30043210
[TBL] [Abstract][Full Text] [Related]
38. Certolizumab pegol in combination with dose-optimised methotrexate in DMARD-naïve patients with early, active rheumatoid arthritis with poor prognostic factors: 1-year results from C-EARLY, a randomised, double-blind, placebo-controlled phase III study.
Emery P; Bingham CO; Burmester GR; Bykerk VP; Furst DE; Mariette X; van der Heijde D; van Vollenhoven R; Arendt C; Mountian I; Purcaru O; Tatla D; VanLunen B; Weinblatt ME
Ann Rheum Dis; 2017 Jan; 76(1):96-104. PubMed ID: 27165179
[TBL] [Abstract][Full Text] [Related]
39. Post-hoc analysis showing better clinical response with the loading dose of certolizumab pegol in Japanese patients with active rheumatoid arthritis.
Takeuchi T; Yamamoto K; Yamanaka H; Ishiguro N; Tanaka Y; Eguchi K; Watanabe A; Origasa H; Kobayashi M; Shoji T; Togo O; Miyasaka N; Koike T
Mod Rheumatol; 2016 Jul; 26(4):473-80. PubMed ID: 26472043
[TBL] [Abstract][Full Text] [Related]
40. Matrix metalloproteinase-3 and the 7-joint ultrasound score in the assessment of disease activity and therapeutic efficacy in patients with moderate to severe rheumatoid arthritis.
Zhou L; Wang G; Liu X; Song J; Chen L; Xu H
Arthritis Res Ther; 2017 Nov; 19(1):250. PubMed ID: 29141665
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
